Sistemic’s SistemPSCCheck™ assay meets new guidelines released by International Society for Stem Cell Research (ISSCR) for stem cell research.

Release Date: 14 August 2023

This week, the International Society for Stem Cell Research (ISSCR) released a new set of guidelines and standards in an effort to improve the rigor and reproducibility of data obtained from human stem cell research.

The ISSCR is the most prominent international stem cell research society that have previously governed the field accepted guidelines for stem cell research. These updated standards, which establish the minimum characterization and reporting criteria for scientists working in the field, draws from previous studies to improve the reproducibility of research using pluripotent stem cells from human origin.

In addition to this, one of the outcomes of this project is the development of updated reporting practices for publishing results with human pluripotent cells checklist. This is intended to help researchers to prepare manuscripts with standardised requirements for inclusion of data obtained when using pluripotent stem cells (PSCs) in an effort to standardise reporting in the field and ensure robust studies with clinically relevant, reproducible data.

Sistemic is pleased to report that its SistemPSCCheck™ assay for the detection of residual PSCs in a derived cell product meets all the outlined requirements in the updated standards. Our existing reporting framework is in line with the guidelines suggested by the ISSCR.

Dr. Liam Brennan, Vice President of Scientific Research at Sistemic stated “We have always focused on ensuring that Sistemic and its products offer the highest standards for our collaborators. The release of these guidelines is further confirmation and affirmation of our approach”.

Jim Reid, Chairman and CEO added “The field of Stem Cell research offers real promise for so many diseases and conditions which to date have been intractable, but it is also vital that guidelines and standards are developed to ensure the best possible outcomes. Sistemic welcomes the updated guidelines”.

Sistemic Scotland Ltd

2317 Maryhill Road, Block 3, Unit 3/4
Glasgow, G20 0SP
0141 946 9682

Sistemic Ltd announce expansion of patent portfolio covering the use of microRNAs as predictive analytes for cellular function.

Release Date: July 16th, 2020

Glasgow, United Kingdom; 16th July 2020: Sistemic Ltd. is pleased to announce that it has received Notification of Intention to Grant by the United Kingdom Intellectual Property Office (UKIPO) for the patent application entitled “Functional Prediction of MSCs” (UK Patent Application No. 1608086.3).

The Notification of Intention to Grant is sent to the applicant when the UKIPO intends to issue a patent. The patent covers microRNA (miRNA) expression analysis of Mesenchymal Stem Cells (MSCs) from different donors to identify miRNAs that predict subsequent cellular function to support donor screening and the development of MSCs as cell therapy products.

The grant of this patent is another exciting expansion of Sistemic’s existing patent portfolio for the use of miRNAs for donor screening, stem cell characterisation, potency assay development and quality control of stem cell products.

The company is pursuing patents covering the application of miRNAs in the development and Quality Assurance of cell therapies and is advancing its patent portfolio in most major world markets including Europe, USA, Japan and a number of other territories.

Jim Reid, CEO stated, “The stem cell field holds phenomenal promise to treat many diseases which are currently untreatable. As such, it is of great interest. However, understanding the function of these cells can be difficult. This patent demonstrates the strength of Sistemic’s technologies to help stem cell companies bring products to market which are better characterised and safer to use. The ability to predict cellular function prior to expensive manipulation or use will be of great advantage to companies in the field and paves the way for better and more effective products. ”.

David Mallinson, VP of Scientific Operations added, “It is of critical importance to Sistemic to be able to protect our core intellectual property. The granting of this patent is another significant milestone for Sistemic”.


Sistemic’s primary business is focused on providing innovative microRNA-based problem-solving services and products to areas of unmet need within Pharmaceutical, Biotechnology and the Cell and Gene Therapy research, development and manufacturing markets.

For more information contact: press@sistemic.co.uk